COCHLEAR IMPLANTS (FOR NEBRASKA ONLY)

Policy Number: CS019NE.L

Effective Date: April 1, 2019

This Medical Policy only applies to the state of Nebraska.

COVERAGE RATIONALE

The following are proven and medically necessary when used according to U.S. Food and Drug Administration (FDA) labeled indications, contraindications, warnings and precautions:

- Non-hybrid cochlear implantation (unilateral or bilateral) for treating individuals who meet all of the following criteria:
  - Diagnosis of bilateral prelingual or postlingual moderate-to-profound Sensorineural Hearing Loss; and
  - Limited benefit (refer to the FDA section) from appropriate hearing (or vibrotactile) aids. A hearing aid trial is not required in an individual with a concern for meningitis-related cochlear ossification; and
  - Ability to follow or participate in a program of aural rehabilitation; and
  - Freedom from middle ear infection, an accessible cochlear lumen that is structurally suited to implantation, and freedom from lesions in the auditory nerve and acoustic areas of the central nervous system

- Hybrid cochlear implantation for treating individuals who meet all of the following criteria:
  - Diagnosis of bilateral severe-to-profound Sensorineural Hearing Loss in the mid-to-high frequencies with residual low-frequency hearing sensitivity; and
  - Ability to follow or participate in a program of aural rehabilitation; and
  - Freedom from middle ear infection, an accessible cochlear lumen that is structurally suited to implantation, and freedom from lesions in the auditory nerve and acoustic areas of the central nervous system

DEFINITIONS

Degree of Hearing Loss:

<table>
<thead>
<tr>
<th>Degree of Hearing Loss</th>
<th>Range (dbHL = Decibels Hearing Level)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Hearing</td>
<td>-10 to 15 dBHL</td>
</tr>
<tr>
<td>Slight Loss</td>
<td>16 to 25 dBHL</td>
</tr>
<tr>
<td>Mild Loss</td>
<td>26 to 40 dBHL</td>
</tr>
<tr>
<td>Moderate Loss</td>
<td>41 to 55 dBHL</td>
</tr>
<tr>
<td>Moderately Severe Loss</td>
<td>56 to 70 dBHL</td>
</tr>
<tr>
<td>Severe Loss</td>
<td>71 to 90 dBHL</td>
</tr>
</tbody>
</table>
Degree of Hearing Loss | Range (dBHL = Decibels Hearing Level)
--- | ---
Profound Loss | 91 dBHL or more

(ASHA, Type, Degree and Configuration of Hearing Loss; Clark, 2015, 1981)

**Sensorineural Hearing Loss (SNHL):** Occurs when there is damage to the inner ear (cochlea), or to the nerve pathways from the inner ear to the brain. Most of the time, SNHL cannot be medically or surgically corrected. This is the most common type of permanent hearing loss (American Speech-Language-Hearing Association [ASHA]. Sensorineural Hearing Loss).

**APPLICABLE CODES**

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
</table>
| 69930 | Cochlear device implantation, with or without mastoidectomy

CPT® is a registered trademark of the American Medical Association

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L8614</td>
<td>Cochlear device, includes all internal and external components</td>
</tr>
<tr>
<td>L8615</td>
<td>Headset/headpiece for use with cochlear implant device, replacement</td>
</tr>
<tr>
<td>L8616</td>
<td>Microphone for use with cochlear implant device, replacement</td>
</tr>
<tr>
<td>L8617</td>
<td>Transmitting coil for use with cochlear implant device, replacement</td>
</tr>
<tr>
<td>L8618</td>
<td>Transmitter cable for use with cochlear implant device or auditory osseointegrated device, replacement</td>
</tr>
<tr>
<td>L8619</td>
<td>Cochlear implant external speech processor and controller, integrated system, replacement</td>
</tr>
<tr>
<td>L8627</td>
<td>Cochlear implant, external speech processor, component, replacement</td>
</tr>
<tr>
<td>L8628</td>
<td>Cochlear implant, external controller component, replacement</td>
</tr>
<tr>
<td>V5273</td>
<td>Assistive listening device, for use with cochlear implant</td>
</tr>
</tbody>
</table>

**DESCRIPTION OF SERVICES**

While hearing loss may relate to abnormalities in the sound conduction system of the outer and middle ear, most severe hearing deficits in newborns and the elderly result from sensorineural abnormalities, particularly cochlear hair cell loss which limits the ability of the cochlea to convert sound vibrations into nerve impulses. This type of hearing loss is usually irreversible and has been treated with rehabilitation strategies involving hearing aids, sign language, and speech and language therapy. Amplification does not replace the function of lost cochlear hair cells and often cannot provide adequate hearing in the case of severe cochlear hair loss. If appropriate neural elements in the ear are intact and functional, it is possible to stimulate auditory nerve impulses with a cochlear implantation device to improve sound recognition.

Auditory neuropathy is described as a hearing disorder in which sound enters the inner ear normally but the transmission of signals from the inner ear to the brain is impaired. People with auditory neuropathy may have normal hearing, inconsistencies in their hearing, or Sensorineural Hearing Loss ranging from mild to severe. Even though a person with auditory neuropathy may be able to hear sounds, they may still have trouble understanding speech clearly. It can affect people of all ages, from infancy through adulthood. The exact number of people affected by auditory neuropathy is not known, but the condition is thought to affect a relatively small percentage of people who are deaf or hearing-impaired (National Institutes of Health, 2011).

The cochlear implant (CI) is composed of three parts, which include external components and two internal surgically implanted components. Externally, a microphone, speech processor, and transmitter coil with cables are worn. The speech processor converts sound into electrical stimuli. Internal components include an antenna and electrodes. The antenna electromagnetically captures the stimuli transmitted by the speech processor and directs this information to internal electrodes. The electrodes provide direct electrical stimulation to the auditory nerve, bypassing the transducer.
Potential candidates for cochlear implant must obtain limited benefit from hearing aids, which typically is determined by administering age appropriate word/sentence recognition testing while the individual wears appropriately fitted hearing aids, often described as the best-aided condition. Cochlear implants may be considered for use in individuals who acquired hearing loss after development of speech (postlingual), during development of speech (perilingual), or before development of speech (prelingual). After receiving cochlear implantation, devices are programmed on an individual basis and recipients must undergo training and rehabilitation to learn to use auditory cues obtained from the device. Advantages associated with cochlear implants include significantly improved lip reading ability, improved recognition of environmental sounds, and improved speech intelligibility.

Typically, individuals undergo unilateral CI. However, bilateral CI is also performed with two devices implanted at the same time or sequentially. Theoretical advantages of bilateral implantation are improved localization of sound and improved speech recognition in noisy environments. Bilateral cochlear implantation in children is being investigated as a means to improve their access to phonologic inputs, thus providing the basis for oral language learning.

Hybrid cochlear implants use electric-acoustic stimulation (EAS) that simultaneously combines electro-stimulation technology used in traditional cochlear implants with acoustic amplification technology used in hearing aids. Hybrid cochlear devices are intended to be used in individuals with severe to profound Sensorineural Hearing Loss with residual low-frequency hearing sensitivity. To preserve low-frequency hearing, implant electrodes are designed to minimize cochlear trauma and are placed in the cochlea using an optum surgical approach (Friedland and Runge-Samuelson, 2009).

**CLINICAL EVIDENCE**

### Non-Hybrid Cochlear Implantation in Adults

Health Quality Ontario (2018) completed a health technology assessment, which included an evaluation of clinical benefits and harms and patient preferences related to bilateral cochlear implantation. A systematic literature search was performed for studies on bilateral cochlear implantation in adults and children from inception to March 2017. Finally, interviews were conducted with adults who have sensorineural hearing loss and unilateral or bilateral cochlear implants, and with parents of children with bilateral cochlear implants. Twenty-four publications (10 in adults, 14 in children) were included in the clinical evidence review. Compared with unilateral cochlear implantation, bilateral cochlear implantation improved sound localization, speech perception in noise, and subjective benefits of hearing in adults and children with severe to profound sensorineural hearing loss (GRADE: moderate to high). Bilateral cochlear implantation also allowed for better language development and more vocalization in preverbal communication in children (GRADE: moderate). The safety profile was acceptable. Bilateral cochlear implantation was more effective than unilateral cochlear implantation. The authors concluded based on evidence of moderate to high quality, that bilateral cochlear implantation improved hearing in adults and children with severe to profound sensorineural hearing loss. Patients with sensorineural hearing loss reported the positive effects of cochlear implants, and patients with unilateral cochlear implants generally expressed a desire for bilateral implants.

A meta-analysis of data from studies of cochlear implants in adults found that 11 of 16 studies involving unilateral implantation showed a statistically significant improvement in mean speech scores as measured by open-set sentence or multi-syllable word tests. The meta-analysis revealed a significant improvement in quality of life (QOL) after unilateral implantation (Gaylor et al. 2013).

A meta-analysis of data from studies of cochlear implants in adults found that bilateral implantation resulted in significant improvement in at least one communication-related outcome in 12 of 15 studies included in the meta-analysis. Simultaneous bilateral implantation showed significant improvement in communication-related outcomes as compared with unilateral implantation in all but two studies. The quality of life (QOL) outcomes varied after bilateral implantation but in general, the results showed significant improvement in QOL after implantation (Gaylor et al. 2013).

van Zon et al. (2017) conducted a multicenter randomized controlled trial to investigate hearing capabilities and self-reported benefits of simultaneous bilateral cochlear implantation (BiCI) compared with unilateral cochlear implantation (UCI) after a 2-year follow-up and evaluated the learning effect of cochlear implantees over time. Thirty-eight postlingually deafened adults were included in this study and randomly assigned to either UCI or simultaneous BiCI. The primary outcome was speech intelligibility in noise, with speech and noise coming from straight ahead (Utrecht-Sentence Test with Adaptive Randomized Roving levels). Secondary outcomes were speech intelligibility in noise with spatially separated sources, speech intelligibility in silence (Dutch phoneme test), localization capabilities and self-reported benefits assessed with different quality of hearing and quality of life (QoL) questionnaires. The patients were followed for two years and results showed comparable results for the UCI and simultaneous BiCI group, when speech and noise were both presented from straight ahead, however patients in the BiCI group performed significantly better...
than patients in the UCI group, when speech and noise came from different directions, and were better able to localize sounds. These results were consistent with patients’ self-reported hearing capabilities, but not with the questionnaires regarding QoL. The authors found no significant differences on any of the subjective and objective reported outcomes between the 1-year and 2-year follow-up. The authors concluded that this study demonstrates important benefits of simultaneous BiCI compared with UCI that remain stable over time. Bilaterally implanted patients benefit significantly in difficult everyday listening situations such as when speech and noise come from different directions, and are able to localize sounds, which is impossible for unilaterally implanted patients.

In a multicenter randomized clinical trial, Smulders et al. (2016) determined the benefits of simultaneous bilateral cochlear implantation (BCI) compared with unilateral cochlear implantation (UCI) in adults with postlingual deafness. Thirty-eight patients were included in the trial. Nineteen participants were randomized to undergo UCI and 19 to undergo BCI. Fifteen patients in the BCI group used hearing aids before implantation compared with 19 in the UCI group. Otherwise, there were no significant differences between the groups’ baseline characteristics. At 1-year follow-up, there were no significant differences between groups on the Utrecht Sentence Test with Adaptive Randomized Roving levels or the consonant-vowel-consonant test. The BCI group performed significantly better than the UCI group when noise came from different directions. The BCI group was better able to localize sounds. These results were consistent with the patients’ self-reported hearing capabilities. According to the authors, this randomized clinical trial demonstrates a significant benefit of simultaneous BCI above UCI in daily listening situations for adults with postlingual deafness.

In April 2011, a technology assessment was completed for the Agency for Health Care Research and Quality (AHRQ) on the effectiveness of cochlear implants in adults. The assessment included a review of 22 studies and concluded that while the studies reviewed were rated as poor to fair quality, unilateral cochlear implants are effective in adults with sensorineural hearing loss. Pre- and post-cochlear implant scores on multi-syllable tests and open-set sentence tests demonstrated significant gains in speech perception regardless of whether a contralateral hearing aid was used along with the cochlear implant. Additionally, the assessment found health-related quality of life improved with unilateral cochlear implants. The assessment also included a review of 16 studies on bilateral cochlear implantation of fair to moderate quality published since 2004. The assessment concluded that bilateral cochlear implants provide greater benefits in speech perception test scores, especially in noise, when compared to unilateral cochlear implants. However, it was unclear if these benefits were experienced under quiet conditions although benefits increased with longer bilateral cochlear implant usage indicating a need for longer term studies (Raman, 2011).

**Professional Societies**

**American Speech-Language-Hearing Association (ASHA)**

According to a technical report approved by the ASHA, adults with long-term prelingual deafness usually do not develop open-set word recognition abilities. However, these patients may recognize environmental sounds and have improved lip reading ability following cochlear implantation. Cochlear implant recipients with greater amounts of preimplant residual hearing demonstrate superior postimplant spoken word recognition. Presumably, persons with greater residual hearing have a more intact auditory system with a larger number of surviving neural elements to stimulate (ASHA, 2004).

**American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS)**

The AAO-HNS considers unilateral and bilateral cochlear implantation as appropriate treatment for adults and children with severe to profound hearing loss. Based on extensive literature demonstrating that clinically selected adults and children can perform significantly better with two cochlear implants than one, bilateral cochlear implantation is accepted medical practice (AAO-HNS, 2014).

**Non-Hybrid Cochlear Implantation in Children**

Health Quality Ontario (2018) completed a health technology assessment, which included an evaluation of clinical benefits and harms and patient preferences related to bilateral cochlear implantation. A systematic literature search was performed for studies on bilateral cochlear implantation in adults and children from inception to March 2017. Finally, interviews were conducted with adults who have sensorineural hearing loss and unilateral or bilateral cochlear implants, and with parents of children with bilateral cochlear implants. Twenty-four publications (10 in adults, 14 in children) were included in the clinical evidence review. Compared with unilateral cochlear implantation, bilateral cochlear implantation improved sound localization, speech perception in noise, and subjective benefits of hearing in adults and children with severe to profound sensorineural hearing loss (GRADE: moderate to high). Bilateral cochlear implantation also allowed for better language development and more vocalization in preverbal communication in children (GRADE: moderate). The safety profile was acceptable. Bilateral cochlear implantation was more effective than unilateral cochlear implantation. The authors concluded based on evidence of moderate to high quality, that bilateral cochlear implantation improved hearing in adults and children with severe to profound sensorineural hearing loss. Patients with sensorineural hearing loss reported the positive effects of cochlear implants, and patients with unilateral cochlear implants generally expressed a desire for bilateral implants.
Forli et al. (2011) conducted a systematic review to summarize the results of scientific publications on the clinical effectiveness of cochlear implantation (CI) in children. The authors identified seven studies comparing post-CI outcomes in children implanted within the first year of life with those of children implanted after one year of age. The findings in these studies suggested improvements in hearing and communicative outcomes in children receiving implants prior to one year of age. However, it is not clear whether any advantages of early implantation are retained over time. Studies document an advantage in children younger than 18 months of age who received a cochlear implant compared to those implanted at a later stage.

Lammers et al. (2014) evaluated the effectiveness of bilateral cochlear implantation over unilateral implantation in children with sensorineural hearing loss. Twenty-one studies were identified that compared a bilateral cochlear implant group with a unilateral group. No randomized trials were identified. Due to the clinical heterogeneity of the studies statistical pooling was not feasible and a best evidence synthesis was performed. The results of this best evidence synthesis indicate the positive effect of the second implant for especially sound localization and possibly for preverbal communication and language development. There was insufficient evidence to make a valid comparison between bilateral implantation and a bimodal fitting. The authors concluded that although randomized trials are lacking, the results of a best evidence synthesis indicate that the second cochlear implant might be especially useful in sound localization and possibly also in language development.

**Professional Societies**

**American Speech-Language-Hearing Association (ASHA)**

According to a technical report approved by the ASHA, both prelingually and postlingually deafened children are candidates for cochlear implantation if they receive limited benefits from conventional amplification. Cochlear implantation in the early preschool years and possibly in infancy followed by high quality aural rehabilitation and speech training should improve the proportion of children with good speech and language outcomes (ASHA, 2004).

**American Academy of Otolaryngology—Head and Neck Surgery (AAO-HNS)**

The AAO-HNS considers unilateral and bilateral cochlear implantation as appropriate treatment for adults and children with severe to profound hearing loss. Based on extensive literature demonstrating that clinically selected adults and children can perform significantly better with two cochlear implants than one, bilateral cochlear implantation is accepted medical practice (AAO-HNS, 2014).

**American Academy of Pediatrics (AAP)**

In a 2007 position statement on the Principles and Guidelines for Early Hearing Detection and Intervention Programs, the AAP states that cochlear implantation should be given careful consideration for any child who seems to receive limited benefit from a trial with appropriately fitted hearing aids. The AAP also states that the presence of developmental conditions (e.g., developmental delay, autism) in addition to hearing loss should not, as a rule, preclude the consideration of cochlear implantation for an infant or child who is deaf (AAP, 2007).

The AAP statement on cochlear implants in children discusses surgical site infections and prevention and treatment of acute otitis media (AOM) and meningitis. The policy statement indicates that children with profound deafness who are candidates for cochlear implants should receive all age-appropriate doses of pneumococcal conjugate and *Haemophilus influenzae* type b conjugate vaccines and appropriate annual immunization against influenza (Rubin et al. 2010).

**Cochlear Implantation for Auditory Neuropathy**

Fernandes et al. (2015) conducted a systematic review of the literature to summarize the evidence regarding the performance of hearing skills in children with auditory neuropathy spectrum disorder (ANSD) using cochlear implants (CIs). Eighteen articles and two dissertations met the criteria and were included in this systematic review. Of those studies, five were non-randomized controlled trials of high quality, five were characterized as randomized controlled trials of low quality, and ten were clinical outcome studies. The results suggest that after CI use, individuals with ANSD improve in the detection of speech sounds, speech discrimination, and the recognition of words and sentences, but still have difficulty in speech perception in noisy conditions, and that there is no difference in the test scores of the hearing skills of ANSD/CI children and CI children with sensorineural hearing loss, with respect to speech detection, discrimination, and recognition of words and sentences. The authors concluded that additional long-term studies of ANSD/CI children are needed in order to guide the rehabilitation process in this population.

Humphriss et al. (2013) conducted a systematic review to summarize and synthesize current evidence of the effectiveness of cochlear implantation (CI) in improving speech recognition in children with auditory neuropathy spectrum disorder (ANSD). A total of 27 studies were included in the review. All selected studies were observational in design, including case studies, cohort studies, and comparisons between children with ANSD and SNHL. Most children with ANSD achieved open-set speech recognition with their CI. Speech recognition ability was found to be equivalent in CI users (who previously performed poorly with hearing aids) and hearing-aid users. Outcomes following
CI generally appeared similar in children with ANSD and SNHL. Assessment of study quality, however, suggested substantial methodological concerns, particularly in relation to issues of bias and confounding, limiting the robustness of any conclusions around effectiveness. The authors concluded that currently available evidence is compatible with favorable outcomes from CI in children with ANSD. However, this evidence is weak. Stronger evidence is needed to support clinical policy and practice in this area.

In a systematic review, Roush et al. (2011) summarized the current evidence related to the audiologic management of children with auditory neuropathy spectrum disorder (ANSD). The review included 15 studies that addressed cochlear implantation in these patients. Study participants demonstrated improved auditory performance; however, all studies were considered exploratory, and many had methodological limitations. The authors concluded that the clinical evidence related to intervention for ANSD is at a very preliminary stage. The authors stated that additional research is needed to address the efficacy of cochlear implantation in children with ANSD and the impact of this disorder on developmental outcomes.

According to the National Institute on Deafness and Other Communication Disorders, no tests are currently available to determine whether an individual with auditory neuropathy might benefit from a hearing aid or cochlear implant. Researchers are continuing to investigate the potential benefits of cochlear implants for children with auditory neuropathy and are examining why cochlear implants may benefit some people with the condition but not others (National Institutes of Health, 2016, updated 2018).

**Hybrid Cochlear Implants**

Gantz et al. (2018) investigated the stability of residual hearing and speech perception outcomes in individuals who were implanted with a shorter electrode device. Fifty subjects who received a Nucleus Hybrid short electrode cochlear implant (CI) and had a minimum of 2 years (and up to 15 years) of postoperative longitudinal experience were included in the study. Twenty-three subjects received a Nucleus Hybrid S8 (S8); 14 subjects received a Nucleus Hybrid L24 (L24); and 13 received a Nucleus Hybrid S12 (S12). Audiometric thresholds and consonant-nucleus-consonant (CNC) words were collected pre- and postoperatively for up to 15 years for the S8 subjects and for up to 7 years for the S12 and L24 subjects. AzBio Sentences in multi-talker babble was collected for up to 7 years on the S12 and L24 subjects. Longitudinally, 83% of the S8 subjects, 92% of the S12 subjects, and 86% of the L24 subjects maintained a functional hearing pure-tone average (PTA) (125-500 Hz). Predicted change using a piecewise linear mixed model in PTA over time showed a postoperative linear decrease in hearing for each group until 0.5 years, after which the PTA stabilizes and is maintained. The averaged individual data for CNC and AzBio sentences show a significant improvement in scores by 0.25 to 0.5 years postimplantation, after which scores start to reach their maximum. The authors concluded that this long-term study demonstrates that acoustic-electric processing hearing and improvement in speech understanding in quiet and in noise can be accomplished and sustained for many years with a short electrode CI.

Pillsbury et al. (2018) evaluated the safety and effectiveness of the MED-EL Electric-Acoustic Stimulation (EAS) System (a hybrid cochlear implant), for adults with residual low-frequency hearing and severe-to-profound hearing loss in the mid to high frequencies in a prospective, repeated measures study. Subjects implanted with PULSAR or SONATA cochlear implants with FLEX electrode arrays were included in the study. Subjects were fit postoperatively with an audio processor, combining electric stimulation and acoustic amplification. Unaided thresholds were measured preoperatively and at 3, 6, and 12 months postactivation. Speech perception was assessed at these intervals using City University of New York sentences in noise and consonant-nucleus-consonant words in quiet. Subjective benefit was assessed at these intervals via the Abbreviated Profile of Hearing Aid Benefit and Hearing Device Satisfaction Scale questionnaires. Sixty-seven of 73 subjects (92%) completed outcome measures for all study intervals. Of those 67 subjects, 79% experienced less than a 30dB HL low-frequency pure-tone average (250-1000Hz) shift, and 97% were able to use the acoustic unit at 12 months postactivation. In the EAS condition, 94% of subjects performed similarly to or better than their preoperative performance on City University of New York sentences in noise at 12 months postactivation, with 85% demonstrating improvement. Ninety-seven percent of subjects performed similarly or better on consonant-nucleus-consonant words in quiet, with 84% demonstrating improvement. The investigators concluded that the MED-EL EAS System is a safe and effective treatment option for adults with normal hearing to moderate sensorineural hearing loss in the low frequencies and severe-to-profound sensorineural hearing loss in the high frequencies who do not benefit from traditional amplification.

Roland et al. (2018) assessed the long-term benefits of implantation in patients with high-frequency sensorineural hearing loss by reviewing the 5-year follow-up on a group of implant recipients who were subjects of the Cochlear™ Nucleus® Hybrid™ L24 Implant System pivotal clinical study (Roland et al., 2016). The results of three related clinical studies were compiled to provide outcome data after 1, 3, and 5 years of implant use in a group of subjects who presented with preoperative high-frequency hearing loss and were implanted with a Nucleus Hybrid L24 cochlear implant. A subset of the 50 adult subjects (N=32) who participated in the Hybrid L24 pivotal Investigational Device Exemption (IDE) completed comprehensive evaluations at 12 months postactivation, 3 years postactivation, and then as part of a postapproval study at 5 years postactivation. Testing included audiometric, speech perception, and
subjective satisfaction measures. Mean unilateral speech perception performance was significantly improved at all postoperative intervals compared to preoperative best-aided results and has remained stable to 5 years postactivation. Ninety-four percent of subjects had measurable hearing, and 72% continued to use electric-acoustic stimulation in the implanted ear after 5 years of implant use. Subjective satisfaction results support objective performance improvements. The authors concluded that the study results demonstrate long-term success of patients with high-frequency hearing loss following Hybrid L24 (Cochlear) cochlear implantation. According to the authors, benefits include speech perception abilities significantly better than those in the preoperative best-aided condition, with additional benefit in those using electric-acoustic stimulation in the implanted ear.

In a prospective single-arm trial, Roland et al. (2016) evaluated the safety and efficacy of acoustic and electric sound processing for individuals with significant residual low-frequency hearing and severe-to-profound high-frequency sensorineural hearing loss. Fifty individuals, ≥ 18 years old, with low-frequency hearing and severe high-frequency loss were implanted with the Cochlear Nucleus Hybrid L24 implant at 10 investigational sites. Preoperatively, subjects demonstrated consonant-nucleus-consonant word scores of 10% through 60% in the ear to be implanted. Subjects were assessed preoperatively, preoperatively, and postoperatively on coprimary endpoints of consonant-nucleus-consonant words, AzBio sentences in noise, and self-assessment measures. Significant mean improvements were observed for coprimary endpoints: consonant-nucleus-consonant words (35.8 percentage points) and AzBio sentences in noise (32.0 percentage points). Ninety-six percent of subjects performed equal or better on speech in quiet and 90% in noise. Eighty-two percent of subjects showed improved performance on speech in quiet and 74% in noise. Self-assessments were positive, corroborating speech perception results. The authors concluded that the Nucleus Hybrid System provides significant improvements in speech intelligibility in quiet and noise for individuals with severe high-frequency loss and some low-frequency hearing.

Kelsall et al. (2017) conducted a prospective, multicenter, nonrandomized, single-arm repeated measures, single-subject design study on the patient-reported outcomes (PROs) from the above clinical trial (Roland et al., 2016) for individuals with significant residual low-frequency hearing and severe-to-profound high-frequency sensorineural hearing loss (SNHL) who received the hybrid cochlear implant (CI). Fifty adults seen in tertiary ambulatory care centers, with severe-to-profound high-frequency SNHL and residual low-frequency hearing with aided word recognition scores between 10 and 60% in the ear to be implanted, and in the contralateral ear greater than or equal to implant ear less than or equal to 80% were evaluated. Speech, spatial and qualities of hearing scale (SSQ), device use questionnaire (DUQ), University of Washington Clinical Assessment of Music Perception (UW-CAMP) were assessed preoperatively and after 6 and 12 months of hybrid CI use. The results showed significant improvements in mean SSQ ratings were demonstrated at 6 and 12 months postactivation overall and for domains related to speech hearing, spatial hearing, and sound quality. Significant improvement was also found for overall satisfaction on the DUQ and across a number of specific listening situations in addition to aspects related to social engagement. UW-CAMP pitch discrimination and melody and timbre recognition abilities were not compromised postoperatively, allowing hybrid subjects to maintain superior music perception abilities than typically observed with standard CIs. The authors concluded that patients who received the hybrid CI demonstrated significant PRO benefits on the SSQ and the DUQ after 6 and 12 months of CI use. In addition, given the opportunity to maintain useful low-frequency acoustic hearing, patients retained music listening abilities, as assessed by the UW-CAMP.

Gantz et al. (2016) describe the final outcomes of a multicenter, longitudinal, single-subject design study of the Nucleus Hybrid S8 CI that took place between 2002 and 2011. Eighty-seven subjects received a Nucleus Hybrid S8 CI in their poorer ear. Speech perception in quiet (Consonant-Nucleus-Consonant [CNC] words) and in noise (Bamford-Kowal-Bench Sentences-In-Noise [BKB-SIN]) were collected pre- and postoperatively at 3, 6, and 12 months. Subjective questionnaire data using the Abbreviated Profile for Hearing Aid Benefit (APHAB) were also collected. Some level of hearing preservation was accomplished in 98% subjects, with 90% maintaining a functional low-frequency pure-tone average (LFPTA) at initial activation. By 12 months, five subjects had total hearing loss, and 80% of subjects maintained functional hearing. CNC words demonstrated that 82.5% and 87.5% of subjects had significant improvements in the hybrid and combined conditions, respectively. The majority had improvements with BKB-SIN. Results also indicated that as long as subjects maintained at least a severe LFPTA, there was significant improvement in speech understanding. Furthermore, all subjects reported positive improvements in hearing in three of the four subscales of the APHAB. According to the authors, the concept of hybrid speech processing has significant advantages for subjects with residual low-frequency hearing. Fourteen subjects requested the Hybrid S8 implant be removed because of dissatisfaction with the device. Most experienced a progressive loss of acoustic hearing in the implant ear.

**Meningitis-Related Cochlear Ossification**

Durisin et al. (2015) determined the impedance values and charge consumption following cochlear implantation post-meningitic deaf children depending on the grade of cochlear ossification and obliteration. Post-meningitic deaf (n=49) and control (n=43) children treated with cochlear implants were included in the study. Impedance and charge values were calculated for each group. The degree of ossification of the cochlea was evaluated from a high-resolution computed tomography (HRCT) scan whereas the degree of obliteration was determined intraoperatively by the surgeon. Pneumococci were the principal pathogen responsible for bacterial meningitis, followed by meningococci. In
HRCT scans, the degree of ossification was 1 and 2 in 29% of patients. The results of the intraoperative assessment of the cochlea showed obliteration grade 1 in 38% and grade 2 in 23% of cases. Children in the meningitis group showed significant higher impedances comparing to the control group. A significantly increased charge consumption was observed in patients with a grade 2 ossification when compared to those without ossification. Discussion Cochlea implanted children with meningitis-related deafness exhibit higher impedances, especially in the region of the basal and middle turn, however, not depending on the degree of cochlear ossification. High impedances and charge in the meningitis group may be explained by alterations in the central auditory pathway or on the electrode surface. The authors concluded that to optimize the outcome in post-meningitic deaf children, surgery is advisable at an early stage prior to the onset of cochlear ossification.

Philponn et al. (2010) proposed guidelines in the management of a profound bilateral sensorineural hearing loss after bacterial meningitis. The study was designed as a retrospective chart review that included 40 patients who had postmeningitic cochlear implantation surgeries. Twenty-seven children and 13 adults with postmeningitic deafness were implanted. Mean age was 3 years 8 months for the children and 44 years and 10 months for the adults. The mean time delay between meningitis and surgery was 2 years 1 month for children and 28 years for adults. Eighteen children (67%) were implanted within a year. Labyrinthitis ossificans was evidenced at surgery in 62% of patients. Intraoperative cochlear ossification was classified according to the scale described by Smullen and Balkany (2005). Stage II ossification was seen in 3 patients within 49 days, with 1 of them as soon as 21 days. There was a partial insertion in 9 patients secondary to ossification. Open-set speech discrimination was achieved by 37% of the children (10 of 27) and 23% of the adults (3 of 13). The authors recommend early cochlear implantation for patients with bilateral profound deafness secondary to meningitis.

**Aural Rehabilitation**

Brodie et al. (2018) conducted a systematic literature review to evaluate the impact of different types of hearing rehabilitation after hearing loss and their impact on quality of life. A systematic literature search was conducted on Pubmed which retrieved 549 articles. Of these, 29 articles regarding cochlear implants, bone anchored hearing devices and traditional amplification hearing aids were systematically reviewed. The main finding was that hearing rehabilitation is beneficial in all types of hearing loss and treatment regarding quality of life. However, bone-anchored hearing devices and cochlear implants were shown to produce greater improvements in terms of quality of life than conventional hearing aids. The authors concluded that hearing rehabilitation has a positive impact on quality of life after hearing loss.

**Additional Search Terms**

Cochlear prosthesis

**U.S. FOOD AND DRUG ADMINISTRATION (FDA)**

**Cochlear Implants (Non-Hybrid)**

At the present time, FDA-approved cochlear implant devices are manufactured by Cochlear™ (previously Cochlear Corp.), Advanced Bionics Corp., and MED-EL Corp. Since the first cochlear implant device was approved in the 1980s, these devices have undergone progressive technological refinement, and approved indications for their use gradually have expanded and have become more specific. The currently marketed cochlear implant devices are indicated for 1) adults (age 18 years or older) with severe-to-profound or moderate-to-profound, bilateral, sensorineural hearing loss or 2) children age 12 months or older with bilateral, sensorineural hearing loss who obtain limited benefit from appropriately fitted hearing aids. Specific criteria vary with the device. FDA approval language does not address unilateral or bilateral use.

The FDA labeled indications for currently marketed non-hybrid cochlear implants are summarized in the following table:

<table>
<thead>
<tr>
<th>FDA-Approved Cochlear Implants (Non-Hybrid)</th>
<th>FDA Labeled Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Advanced Bionics®</strong></td>
<td><strong>Adults</strong></td>
</tr>
<tr>
<td>• <a href="https://www.advancedbionics.com/content/advancedbionics/us/en/home.html">https://www.advancedbionics.com/content/advancedbionics/us/en/home.html</a></td>
<td>• 18 years of age or older</td>
</tr>
<tr>
<td>• HiResolution™ Bionic Ear</td>
<td>• Severe-to-profound, bilateral sensorineural hearing loss [≥70 decibels (dB)]</td>
</tr>
<tr>
<td></td>
<td>• Postlingual onset of severe or profound hearing loss</td>
</tr>
<tr>
<td></td>
<td>• Limited benefit from appropriately fitted hearing aids, defined as scoring 50% or less on a test of open-set sentence recognition (HINT Sentences)</td>
</tr>
<tr>
<td>Cochlear Implants (Non-Hybrid)</td>
<td>FDA Labeled Indications</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td><strong>System (HiRes 90K)</strong></td>
<td><strong>Children</strong></td>
</tr>
<tr>
<td>- Predecessors:</td>
<td>- 12 months through 17 years of age</td>
</tr>
<tr>
<td>- Clarion Multi-Strategy</td>
<td>- Profound, bilateral sensorineural deafness (≥90 dB)</td>
</tr>
<tr>
<td>- Clarion HiFocus</td>
<td>- Use of appropriately fitted hearing aids for at least 6 months in children 2 through 17 years of age, or at least 3 months in children 12 through 23 months of age. The minimum duration of hearing aid use is waived if x-rays indicate ossification of the cochlea</td>
</tr>
<tr>
<td><strong>FDA-Approved Cochlear Implants (Non-Hybrid)</strong></td>
<td><strong>Little or no benefit from appropriately fitted hearing aids</strong></td>
</tr>
<tr>
<td><em>Cochlear™ Nucleus®</em></td>
<td>- In younger children (&lt;4 years of age), lack of benefit is defined as a failure to reach developmentally appropriate auditory milestones (such as spontaneous response to name in quiet or to environmental sounds) measured using the Infant-Toddler Meaningful Auditory Integration Scale or Meaningful Auditory Integration Scale or ≤20% correct on a simple open-set word recognition test (Multisyllabic Lexical Neighborhood Test) administered using monitored live voice (70 dB SPL)</td>
</tr>
<tr>
<td><a href="http://www.cochlear.com">http://www.cochlear.com</a></td>
<td>- In older children (≥4 years of age), lack of hearing aid benefit is defined as scoring ≤12% on a difficult open-set word recognition test (Phonetically Balanced-Kindergarten Test) or ≤30% on an open-set sentence test (Hearing in Noise Test for Children) administered using recorded materials in the soundfield (70 dB SPL)</td>
</tr>
<tr>
<td>- Nucleus® 5 and 6 series of CI devices</td>
<td><strong>Adults</strong></td>
</tr>
<tr>
<td>- Predecessors:</td>
<td>- 18 years of age or older</td>
</tr>
<tr>
<td>- Nucleus 22 Channel Cochlear Implant System</td>
<td>- Bilateral, pre, peri or post-linguistic sensorineural hearing impairment</td>
</tr>
<tr>
<td>- Nucleus 24 Contour Systems</td>
<td>- Moderate-to-profound hearing loss in the low frequencies and profound (≥90 dB HL) hearing loss in the mid to high speech frequencies</td>
</tr>
<tr>
<td>- Nucleus Freedom</td>
<td>- Limited benefit from appropriate binaural hearing aids. Limited benefit from amplification is defined by test scores of 50% correct or less in the ear to be implanted (60% or less in the best-aided listening condition) on tape-recorded tests of open set sentence recognition.</td>
</tr>
<tr>
<td><strong>Med El®</strong></td>
<td><strong>Children 12 to 24 Months of Age</strong></td>
</tr>
<tr>
<td>- Maestro® (Sonata or Pulsar)</td>
<td>- Limited benefit from appropriate binaural hearing aids. In younger children, limited benefit is defined as lack of progress in the development of simple auditory skills in conjunction with appropriate amplification and participation in intensive aural habilitation over a three to six month period. It is recommended that limited benefit be quantified on a measure such as the Meaningful Auditory Integration Scale or the Early Speech Perception test.</td>
</tr>
<tr>
<td><strong>Med El®</strong></td>
<td><strong>Children 25 Months Through 17 years of Age</strong></td>
</tr>
<tr>
<td>- Maestro® (Sonata or Pulsar)</td>
<td>- Limited benefit from appropriate binaural hearing aids. In older children, limited benefit is defined as ≤ 30% correct on the open set Multisyllabic Lexical Neighborhood Test (MLNT) or Lexical Neighborhood Test (LNT), depending upon the child’s cognitive and linguistic skills. A 3 to 6 month hearing aid trial is recommended for children without previous aided experience.</td>
</tr>
<tr>
<td>See the following for more information:</td>
<td><strong>Med El®</strong></td>
</tr>
<tr>
<td>(Accessed January 7, 2019)</td>
<td><strong>Med El®</strong></td>
</tr>
<tr>
<td><strong>Adults</strong></td>
<td>- 18 years of age or older</td>
</tr>
<tr>
<td>- Severe-to-profound bilateral sensorineural hearing loss (≥ 70dB)</td>
<td>- Limited benefit from appropriate binaural hearing aids defined as 40% correct or less in Hearing In Noise Test (HINT) sentences with best-aided listening condition</td>
</tr>
</tbody>
</table>
Children
- 12 months through 17 years of age with profound bilateral sensorineural hearing loss (≥ 90dB)
- Limited benefit from appropriate binaural hearing aids
  - In younger children, little or no benefit is defined by lack of progress in the development of simple auditory skills with hearing aids over a 3-6 month period
  - In older children, lack of aided benefit is defined as < 20% correct on the Multisyllabic Lexical Neighborhood Test (MLNT) or Lexical Neighborhood Test (LNT) depending upon the child's cognitive ability and linguistic skills
  - A 3 to 6 month trial with hearing aids is required if not previously experienced with hearing aids. Radiologic evidence of cochlear ossification may justify a shorter trial with amplification.

See the following for more information:
- http://www.medel.com/indications/
  (Accessed January 7, 2019)

Hybrid Cochlear Implants
The Nucleus® Hybrid™ L24 Cochlear Implant System (Cochlear Limited; Cochlear Americas) was approved by the FDA on March 20, 2014. According to the approval order statement, the Nucleus Hybrid L24 Cochlear Implant System is intended to provide electric stimulation to the mid-to-high frequency region of the cochlea and acoustic amplification to the low frequency regions, for patients with residual low frequency hearing sensitivity. The system is indicated for unilateral use in patients aged 18 years and older who have residual low-frequency hearing sensitivity and severe to profound high frequency sensorineural hearing loss, and who obtain limited benefit from appropriately fit bilateral hearing aids. Typical preoperative hearing of candidates ranges from normal to moderate hearing loss in the low frequencies (thresholds no poorer than 60 db hl up to and including 500 hz), with severe to profound mid to high frequency hearing loss (threshold average of 2000, 3000, and 4000 hz 75 db hl) in the ear to be implanted, and moderately severe to profound mid to high frequency hearing loss (threshold average of 2000, 3000, and 4000 hz 60 db hl) in the contralateral ear. The Consonant Nucleus Consonant (CNC) word recognition score will be between 10% and 60%, inclusively, in the ear to be implanted in the preoperative aided condition and in the contralateral ear will be equal to or better than that of the ear to be implanted but not more than 80% correct. Prospective candidates should go through a suitable hearing aid trial, unless already appropriately fit with hearing aids. Refer to the following website for more information: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?id=P130016. (Accessed January 7, 2019)

In September 2016, the FDA approved the Med EL EAS™ (Electric Acoustic Stimulation) Hearing Implant System (Med EL Corp.). This system is a hybrid cochlear implant and hearing aid, with the hearing aid integrated into the external sound processor of the cochlear implant. It is the combination of the SYNCHRONY cochlear implant and the SONNET EAS audio processor. The MED-EL EAS System is indicated for partially deaf individuals aged 18 years and older who have residual hearing sensitivity in the low frequencies sloping to a severe/profound sensorineural hearing loss in the mid to high frequencies, and who obtain minimal benefit from conventional acoustic amplification. Typical preoperative hearing of candidates ranges from normal hearing to moderate sensorineural hearing loss in the low frequencies (thresholds no poorer than 65 dB HL up to and including 500 Hz) with severe to profound mid- to high-frequency hearing loss (no better than 70 dB HL at 2000 Hz and above) in the ear to be implanted. For the non-implanted ear, thresholds may be worse than the criteria for the implanted ear, but may not be better. The CNC word recognition score in quiet in the best-aided condition will be 60% or less, in the ear to be implanted and in the contralateral ear. Prospective candidates should go through a suitable hearing aid trial, unless already appropriately fit with hearing aids. Refer to the following website for more information:

The available literature occasionally mentioned other cochlear implantation devices, including the Digisonic® device (M XM Company, Vallauris, France), the Laura device (Cochlear CTEC, Mechelen, Belgium), the 3M device (Cochlear Corp.), and the Ineraid device (Smith & Nephew Richards). However, these devices have not received approval from the FDA (Digisonic, Laura), or are no longer manufactured (3M, Ineraid).
Medicare covers cochlear implantation when criteria are met. Refer to the National Coverage Determination (NCD) for Cochlear Implantation (50.3). Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) exist; see the LCAs for Coding and Billing External Components for Cochlear Implants.

Medicare does not have an NCD that specifically mentions hybrid cochlear implantation. LCDs/LCAs do not exist at this time. (Accessed January 16, 2019)

REFERENCES


POLICY HISTORY/REVISION INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/01/2020</td>
<td>Created state-specific policy version for Nebraska (no change to guidelines)</td>
</tr>
<tr>
<td>04/01/2019</td>
<td>Updated supporting information to reflect the most current clinical evidence, FDA information, and references; no change to coverage rationale or lists of applicable codes</td>
</tr>
<tr>
<td></td>
<td>Archived previous policy version CS019.K</td>
</tr>
</tbody>
</table>
INSTRUCTIONS FOR USE

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.